Antiplatelet Drugs Market - Size, Share, Trends, and Forecast, 2022 - 2028

Antiplatelet Drugs Market - Size, Share, Trends, and Forecast, 2022 - 2028

Antiplatelet drugs are most effective for arterial clots that are made largely of platelets. These drugs prevent platelets from clumping and avoid clot formation. To achieve this effect, several of these medications act on receptors and proteins that receive chemical signals and cause cells to bind. Antiplatelet drugs are used as a first-line antithrombotic therapy for the management of acute ischemic syndromes and prevent their recurrence. For instance, aspirin blocks a blood-clotting chemical called thromboxane. The drug is sold under various brand names, such as Ecotrin, Aspir, Bayer, and Easprin. Aspirin is often prescribed to people experiencing a heart attack as the drug can effectively and rapidly inhibit platelet activity and growth of blood clot, thereby maintaining some measure of blood flow.
Market Dynamics
Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. According to a report American Diabetes Association, in 2015, around 30.3 million people in the U.S suffered from diabetes, which was 9.4% of the country’s total population. According to a report by American Heart Association (AHA), in 2013, cardiovascular diseases accounted for over 17.3 million deaths worldwide, representing 31% of all deaths. According to the same source, CVDs are projected to affect 23.6 million people by 2030.
Moreover, increasing geriatric population, which is associated with high susceptibility to chronic diseases related to cardiac disorders is expected to boost growth of the global antiplatelet drugs market. According to the American Heart Association 2016 data, an estimated 85.6 million American adults suffer from 1 or more types of cardiovascular disease and 43.7 million of these are estimated to be 60 years or more.
However, side effects associated with antiplatelet drugs including bleeding is expected to adversely impact antiplatelet drugs market growth during the forecast period. Unforeseen incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have hampered the development of superior next generation antiplatelet therapies.
Key features of the study:

This report provides in-depth analysis of the global antiplatelet drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antiplatelet drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global antiplatelet drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for antiplatelet drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Antiplatelet Drugs Market, By Drug Class:

Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors

Global Antiplatelet Drugs Market, By Mode of Administration:

Oral
Intravenous

Global Antiplatelet Drugs Market, By Application:

Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others

Global Antiplatelet Drugs Market, By Region:

North America

By Country:

U.S.
Canada

By Drug Class:

Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors

By Mode of Administration:

Oral
Intravenous

By Application:

Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others

Europe

By Country:

U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe

By Drug Class:

Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors

By Mode of Administration:

Oral
Intravenous

By Application:

Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others

Asia Pacific

By Country:

Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific

By Drug Class:

Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors

By Mode of Administration:

Oral
Intravenous

By Application:

Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others

Latin America

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

By Drug Class:

Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors

By Mode of Administration:

Oral
Intravenous

By Application:

Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others

Middle East

By Country:

GCC
Israel
Rest of Middle East

By Drug Class:

Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors

By Mode of Administration:

Oral
Intravenous

By Application:

Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others

Africa

By Country:

South Africa
Central Africa
North Africa

By Drug Class:

Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors

By Mode of Administration:

Oral
Intravenous

By Application:

Angioplasty
Arterial Thrombosis
Myocardial Infarction
Percutaneous Coronary Interventions
Others

Company Profiles

AstraZeneca Plc*

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo, Inc.
Eli Lilly and Company
Merck & Co., Inc.
Otsuka Pharmaceutical Company, Ltd.
Sanofi
The Medicines Company

“*” marked represents similar segmentation in other categories in the respective section.